DWA
KRYS icon

Dorsey Wright & Associates’s Krystal Biotech KRYS Stock Holding History

Dorsey Wright & Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-390
Closed -$17K – 337
2020
Q1 		$17K Sell
390
-67
-15% -$3.5K 0.01% 111
2019
Q4 		$25K Hold
457
– – 0.01% 119
2019
Q3 		$16K Hold
457
– – ﹤0.01% 149
2019
Q2 		$18K Buy
457
+114
+33% +$3.73K ﹤0.01% 153
2019
Q1 		$11K Sell
343
-342
-50% -$8.06K ﹤0.01% 166
2018
Q4 		$14K Buy
+685
New +$14.3K ﹤0.01% 211

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dorsey Wright & Associates's KRYS Position: Q2 2020 in Review

Dorsey Wright & Associates sold out of Krystal Biotech (KRYS) in Q2 2020, closing a stake of 390 shares — an estimated $17K sold.

Dorsey Wright & Associates first reported a position in KRYS in Q4 2018 and held it in 6 quarters. The position peaked at $25K in Q4 2019. 110 funds tracked by Wall St. Rank hold KRYS as of Q2 2020.

  • Dorsey Wright & Associates reported no remaining Krystal Biotech position as of Q2 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 390 Krystal Biotech shares in Q2 2020, an estimated $17K.
  • Dorsey Wright & Associates first reported a position in Krystal Biotech in Q4 2018 and held it in 6 quarters.
  • Dorsey Wright & Associates's Krystal Biotech position peaked at $25K in Q4 2019.
  • 110 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2020.

Based on Dorsey Wright & Associates's 13F filing for Q2 2020, filed 23 Jul 2020.